VirTIGO Biotechnology, Inc

We are developing novel, host-based therapeutic approaches for the treatment and prophylaxis of SARS-CoV-2, the virus that causes COVID-19.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Atlanta, GA, USA
  • Currency USD
  • Founded April 2020
  • Employees 6
  • Incorporation Type C-corp
  • Website virtigobio.com

Company Summary

VirTIGO is a visionary biotech company developing host-based therapeutics against SARS-CoV-2, the virus that causes COVID-19, and a host-based genetic test able to identify low-risk/high-risk individuals for infection. VirTIGO is a spin-off company from G3 Therapeutics. G3 has raised $40MM to build its biological Big Data-based platform anchored in human genetic target validation. VirTIGO licensed G3's data to combat viral diseases.

Team

  • Karl Blass
    Founder and COO

    Serial entrepreneur

  • Brad Brown
    Founder

    Co-Founder; G3 Therapeutics
    Had recruited over 25,000 patients in trials
    Had executed on over 30 clinical programs

  • Szilard Voros
    Founder and CEO

    Physician by training; serial entrepreneur. Founder and CEO of G3 Therapeutics; Had raised $40MM in capital.

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free